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ess: judithmak@hkucc.Summary Airway epithelial cells are the first targets of environmental stimuli and
local cytokines. Pyocyanin-induced synergism with interleukin (IL)-1 or tumour
necrosis factor (TNF) in triggering IL-8 release has been documented previously. In
this study, IL-8 mRNA and protein expression were examined in cultured human
bronchial epithelial cells (BEAS-2B) stimulated with pyocyanin alone, and in
combination with IL-1b or phorbol 12,13-dibutyrate (PDBu) in the absence and
presence of a group of glucocorticoids. IL-8 mRNA was measured by RT-PCR, and IL-8
protein by ELISA (cell supernatants). Pyocyanin alone produced no increase in IL-8
mRNA and release. However, pyocyanin upregulated the stimulatory effect of IL-1b
or PDBu on the release of IL-8 in a dose-dependent manner. The stimulatory effect of
pyocyanin on the IL-1b- or PDBu-stimulated IL-8 release was reduced in the presence
of dexamethasone, budesonide, and fluticasone. Budesonide and fluticasone were
10-fold more potent than dexamethasone. The protein kinase C (PKC) inhibitor,
Go6976, also significantly reduced the stimulatory effect of pyocyanin on IL-1b, and
PDBu increased IL-8 release. In conclusion, this study shows that PKC signal pathway
seems to be involved in the pyocyanin-mediated upregulation of the IL-1b and PDBu-
induced IL-8 release in BEAS-2B cells. These findings suggest that a vicious cycle
perpetuating inflammation may exist in the biologic milieu of bronchiectatic
patients infected with Pseudomonas aeruginosa due to the production of pyocyanin.Elsevier Ltd. All rights reserved.
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Steroids Inhibit pyocyanin-potentiated IL-8 release 1615The priming action of pyocyanin appears to be blocked by glucocorticoids, thus
providing in vitro data in support of the clinical efficacy of inhaled glucocorticoids as
anti-inflammatory drugs.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Pseudomonas aeruginosa (P. aeruginosa) is a Gram-
negative bacterium that colonises the lower
respiratory tract in patients with bronchiectasis,
cystic fibrosis and chronic obstructive pulmonary
disease.1,2 It is believed to stimulate a persistent
host immune response leading to progressive air-
way destruction in the pathogenesis of bronchiec-
tasis. It produces a variety of toxic factors among
which is pyocyanin, a blue phenazine pigment
exotoxin, which is present at concentrations of up
to 100 mM (27 mg/ml) in the sputum of patients
with bronchiectasis and cystic fibrosis, whose lungs
are colonised by this organism.3 Pyocyanin in-
creases interleukin (IL)-8 expression by airway
epithelial cells, and also synergise with tumour
necrosis factor (TNF) and IL-1 in stimulating IL-8
expression.4 IL-8 is a highly potent neutrophil
chemoattractant, and its increase in the presence
of pyocyanin is at least partly responsible for the
influx of neutrophils and the subsequent neutro-
phil-mediated tissue damage in lung diseases
associated with P. aeruginosa.
IL-8 is an established enhancer of neutrophil
function5–7 while nuclear factor-kB (NF-kB), a
transcription factor believed to play a key role in
IL-8 expression.8 NF-kB is normally sequestered in
the cytoplasm by I-kB proteins and is translocated
into the nucleus where it regulates gene transcrip-
tion via binding to specific DNA sequences. Protein
kinase C (PKC) has been shown to regulate airway
epithelial cell gene expression in an NF-kB-depen-
dent manner.9 Phorbol esters, a class of direct PKC
activators,10 have been shown to upregulate IL-8
expression in various cell types.11–14
Glucocorticoids are the widely prescribed med-
ication in the treatment of inflammatory airway
diseases such as asthma. Their known inhibitory
effects on NF-kB activation or IL-8 release stimu-
lated by cytokines or phorbol esters have been
demonstrated in vitro.15,16 We have previously
demonstrated that anti-inflammatory effects of
inhaled glucocorticoids in bronchiectasis in vivo.17
We hypothesise that priming the cells with pyocya-
nin leads to further increase in IL-8 release via
IL-1b- or phorbol 12,13-dibutyrate (PDBu)-depen-
dent mechanisms in bronchiectasis. In this study,
we sought to evaluate the effects of glucocorticoidsand to study the involvement of PKC-dependent
signal pathway on the release of IL-8 induced by
pyocyanin in the presence of IL-1b or PDBu.Methods
Materials
Pyocyanin was prepared by photolysis of 700mg
phenazine methosulphate in 1.5 l of Tris Buffer
(0.1M, pH 7.0) for 3 days as previously de-
scribed.18,19 The solution was made alkaline
(pH411) and pyocyanin was extracted into chloro-
form (5 400ml). Crude pyocyanin was chromato-
graphed on a column of silica (60 3 cm) eluting in
chloroform:methanol (85:15 v/v). The blue pig-
ment was re-chomatographed on fresh silica to
form a product, which was essentially pure as
judged by HPLC, UV absorbance and electrospray
mass spectrometry.
IL-1b was purchased from Peprotech Inc. (Rocky
Hill, NJ, USA). PDBu was purchased from Merck
Biosciences (San Diego, CA, USA). Dexamethasone
and budesonide were purchased from Sigma
(St. Louis, MO, USA). Fluticasone was kindly
supplied by GlaxoSmithKline (Philadelphia, PA,
USA).
Cell cultures
The human bronchial epithelial cell line BEAS-2B
[American Type Culture Collection (ATCC),
Rockville, MD, USA] was cultured in keratinocyte
serum-free media [K-SFM; Gibco (Carlsdad, CA,
USA)] supplemented with 5 ng/ml epidermal
growth factor (EGF) and 50 mg/ml bovine pituitary
extract. Cells were maintained in a humidified
incubator at 37 1C with 95% (v/v) air and 5% (v/v)
CO2, and replenished with fresh media every 2–3
days. Passages 42–48 with 80–90% confluence were
used throughout this study.
Drug treatments
Treatments of IL-1b, PDBu or pyocyanin alone in
various concentrations, as well as pyocyanin (5mg/ml)
in combination with IL-1b (1 ng/ml) or PDBu
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the study. The selected concentrations are within
the values reported by Bergmann and co-workers in
cultured airway epithelial cells.20 Parallel incuba-
tions of cells in culture medium alone or containing
the relevant concentrations of solvents such as
absolute ethanol or DMSO were taken as controls.
After incubations for various time points up to 4 h,
cells were harvested for total RNA extraction. For
IL-8 release, the cell-free supernatants were
harvested after treatments for 18 h, and assayed
for IL-8. To study the potential effects of various
anti-inflammatory drugs on the stimulated IL-8
production, cells were pre-incubated with various
concentrations of glucocorticoids or a selective
inhibitor of classic PKC isoforms (Go6976) for 30min
at 37 1C before exposure to pyocyanin in the
presence of either IL-1b or PDBu for further 18 h
and supernatants harvested for IL-8 assay.
Cell viability assay
Cell viability was assessed using the 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide
[thiazolyl blue tetrazolium bromide (MMT)] assay
(Sigma, St. Louis, MO, USA) according to the
manufacturer’s instructions.
Reverse transcription-polymerase chain
reaction (RT-PCR)
The expression of IL-8 mRNA was quantified by
semi-quantitative RT-PCR analysis, using glyceral-
dehydes 3-phosphate dehydrogenase (GAPDH)
mRNA as an internal standard. Total cellular RNA
was isolated from cells by using TRI reagent
(Molecular Research Center, Inc., Cincinnati, OH,
USA), and reverse-transcribed using a random
hexadeoxynucleotide primer and ImProm II reverse
transcriptase (Promega Corp., Madison, USA) in
20 ml volume. PCR amplication was performed by
using 0.75 ml of cDNA, 0.1 ml of Hot Star Taq
polymerase (Qiagen, Inc., Valencia, CA, USA),
0.5 ml of deoxyribonucleotide triphosphate (dNTP)
mix, 0.5 ml of each specific sense and anti-sense
primer at 12.5 mM, and 2 ml of reaction buffer
(containing 15mM MgCl2) made up to a final volume
of 20 ml with DEPC-treated water. Hot-start method
was carried out to enhance the sensitivity and
specificity of amplification. The PCR products were
analysed on 2% agarose gel. The primer sequences
and product sizes were as follows: IL-8 forward
50-AGA TGT CAG TGC ATA AAG ACA-30, reverse
50-TGA ATT CTC AGC CCT CTT CAA AAA-30, 200 base
pair (bp); and GAPDH forward 50-GGT CAT CCC TGAGCT GAA CG-30, reverse 50-TCC GTT GTC ATA CCA
GGA AA-30, 283 bp.Measurement of IL-8
Cells were cultured in 12-well tissue culture plates
until reaching 80–90% confluence. Cells were cultured
in serum-free medium without growth supplements
for 24h prior to treatment. The medium was
harvested at 18h after treatment and stored at
20 1C until assay. IL-8 was determined by enzyme-
linked immunosorbent assay (ELISA), using commer-
cially available kits (BD Biosciences-Pharmingen, San
Diego, CA, USA). Briefly, 96-well ELISA plates (Iwaki,
Funabashi, Chiba, Japan) were coated overnight with
monoclonal antibody against human IL-8 diluted in
0.1M bicarbonate buffer (pH 9.6). In between the
steps, plates were washed three times with 0.05%
Tween 20 in phosphate-buffered saline (PBS), except
before adding working detector (five times) and
substrate solution (seven times). The plates were
blocked for 1h with assay diluent (10% FBS in PBS).
Samples were then diluted in assay diluent, and
added to the wells and left for 2h to allow binding.
Working detector, comprising biotinylated anti-hu-
man IL-8 antibody and avidin–horseradish peroxidase
conjugate diluted 200-fold, was added and left for
1h. Antibody binding was visualised by adding
substrate solution (tetramethylbenzidine and hydro-
gen peroxide). Development of colour was stopped by
the addition of 1M H2SO4, and the absorbance at
450nm was measured with l correction at 570nm.
Values were determined relative to a standard curve
(3.13–200pg/ml). The reproducibility, calculated as
the coefficient of variation (CV), was 5.5%.Statistical analysis
Data were presented as mean7SEM from at least
three to four independent experiments. Graphs of
fold-increase were expressed as percentage of
basal level while graphs of suppression were
normalised to maximal response. This procedure
controls for variability in IL-8 release among
different passages of the cultured cells in each
independent experiment. In concentration-re-
sponse experiments, the log inhibitory concen-
tration of 50% (IC50) was calculated by non-linear
regression to express compound potency. Data were
analysed as appropriate by paired t-tests or one-
way analysis of variance (ANOVA) with a Bonferro-
ni’s post hoc test, where appropriate, by using
the Prism 3.0 program (GraphPad, San Diego, CA,
USA). A P-valueo0.05 was considered statistically
significant.
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Figure 2 IL-1b or PDBu induce IL-8 release in BEAS-2B
cells. To each well, different concentrations of IL-1b
(0.1–10 ng/ml (A)) or PDBu (0.1–1.0mM (B)) were added
to the cell cultures for 18 h. Supernatants were harvested
for measuring IL-8 by ELISA. Values represented the
mean7SEM of four independent experiments in triplicate.
Figure 1 Expression of IL-8 mRNA in BEAS-2B cells. Total
RNAs were extracted from BEAS-2B cells after various
treatments [IL-1b (1 ng/ml), PDBu (0.3 mM) or pyocyanin
(Pyo, 5 mg/ml) alone or in combination] with the
indicated times, and analysed by RT-PCR with specific
primers for IL-8. GAPDH was analysed to verify similar
cDNA loading.
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Effect of pyocyanin on IL-8 mRNA and
release
There was no pyocyanin-mediated induction of IL-8
mRNA in BEAS-2B cells at any time points (Fig. 1).
IL-1b or PDBu alone induced IL-8 mRNA in a time-
dependent manner, reaching plateau level at 2 h in
these cells, and stimulated IL-8 release in a
concentration-dependent manner at 18 h (Fig. 2).
Medium alone produced trace amounts of IL-8
(11–46 pg/ml). To assess the effect of pyocyanin
on cell viability, MTT assays were performed on
cells incubated with a range of concentrations of
pyocyanin (0.25–40 mg/ml). A 35% loss of cell
viability was observed at 20 mg/ml pyocyanin (data
not shown). Therefore, incubation with pyocyanin
at concentrations up to 10 mg/ml was used, which
produced no increase over basal level.Pyocyanin potentiates the effects of IL-1b-
and PDBu-induced IL-8 release
Incubation of BEAS-2B cells with drug vehicles
(ethanol, DMSO) at different concentrations
showed no significant effects on IL-8 mRNA and
release. Since IL-1b-induced IL-8 release
(2100–8200 pg/ml) was maximal at 1 ng/ml, this
concentration was used for the rest of the experi-
ments. We also chose 0.3 mM of PDBu to be used to
stimulate IL-8 release (1400–3200 pg/ml) through-
out this study, consistent with the previous re-
port.20 Addition of pyocyanin at different
concentrations (1–5 mg/ml) to IL-1b simultaneously
produced greater potentiation (3500-fold increase)in contrast to PDBu (530-fold increase) in the
release of IL-8 at the highest dose of pyocyanin
(5 mg/ml)(Fig. 3), which was not accompanied by
the potentiation of IL-8 mRNA in the combination of
pyocyanin with either IL-1b or PDBu (Fig. 1).Effects of glucocorticoids and PKC inhibitors
on pyocyanin-potentiated IL-8 release
Glucocorticoid suppression of cytokine-induced IL-8
release in bronchial epithelial cells has previously
been demonstrated.16,17 In this study, all three
glucocorticoids showed concentration-dependent
suppression of the stimulatory effect of pyocyanin
on IL-8 release stimulated by IL-1b or PDBu (Figs. 4
and 5). Dexamethasone produced greater inhibi-
tion of IL-8 release stimulated by the combination
of pyocyanin and PDBu than that by pyocyanin
and IL-1b. Other two glucocorticoids (budesonide
and fluticasone) showed similar extent of inhibition
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Figure 3 Effects of pyocyanin (Pyo) on IL-1b- and PDBu-
stimulated IL-8 release in BEAS-2B cells. Cells were
treated with a fixed dose of IL-1b (1 ng/ml (A)) or PDBu
(0.3 mM (B)) and different concentrations of pyocyanin
(1.0–5.0 mg/ml) for 18 h. Supernatants were harvested
for measuring IL-8 by ELISA. Values were normalised to
the average level of IL-8 release in unstimulated cells and
represented the mean7SEM of four independent experi-
ments in triplicate.
N.Y. Pan et al.1618of IL-8 release stimulated by the combination
of pyocyanin with either IL-1b or PDBu. The rank
order of potencies (log IC50 values) was flu-
ticasone (7.37(0.16))Ebudesonide (7.81(0.21))4
dexamethasone (6.23(0.25)) for IL-8 release stimu-
lated by pyocyanin in combination with IL-1b, and
fluticasone (7.77(0.13))Ebudesonide(7.68(0.19))4
dexamethasone (6.67(0.23)) for IL-8 release stimu-
lated by pyocyanin in combination with PDBu.
The involvement of PKC on IL-8 release stimu-
lated by pyocyanin in combination with IL-1b or
PDBu was studied. As shown in Fig. 6, the PKC
inhibitor, Go6976, significantly reduced the stimu-
latory effect of pyocyanin on IL-8 release in the
presence of IL-1b at the highest dose (10 mM) only;
however, potently inhibited IL-8 release stimulated
by pyocyanin in combination with PDBu, even at the
lowest dose (1 mM).Discussion
In the current study, there was no stimulatory
effect of pyocyanin on IL-8 mRNA and IL-8 release
at doses up to 10 mg/ml relative to the unstimu-
lated control. This is rather surprising in contrast to
previous findings that preparations of pyocyanin
and its precursor phenazine-1-carboxylic acid ob-
tained from P. aeruginosa cultures increased IL-8
release.4,21 In the previous studies, different air-
way epithelial cells such as human alveolar epithe-
lial cell line A549 originally derived from carcinoma
type II pneumocytes, human bronchial epithelial
cell line 16-HBEo, and primary human bronchial
epithelial cells were used in which airway epithelial
cell lines (A549 or 16-HBEo) produced 30-fold
more IL-8 than that by primary airway cells.
P. aeruginosa infection in bronchiectasis is pre-
dominantly an airway infection rather than pneu-
monitic process, thus making bronchial epithelial
cells, but not pneumocytes, as the target cells. We
therefore used BEAS-2B, which is an SV-40 adeno-
virus-transformed cell line originally derived from
normal human bronchial epithelial cells. Precisely,
why BEAS-2B cells failed to respond to pyocyanin
stimulation is currently unknown. Furthermore,
synthetic and pure pyocyanin has been used in our
study, compared to a biological preparation of pure
pyocyanin.4 Differences between this study and the
previous ones could be attributed to cell type and
culture conditions, as the primary bronchial epithe-
lial cells and other airway cell lines may have
different properties to BEAS-2B cells in vitro.
Reibman and co-workers have observed that BEAS-
2B cells showed a marked increase in GM-CSF
production, following addition of TNF-a and IL-1b,
but there was no significant response to phorbol
12-myristate 13-acetate (PMA, a direct PKC acti-
vator).22 Primary human bronchial epithelial cells,
on the other hand, responded vigorously to both
cytokines and phorbol esters. There are currently
no literatures indicating that IL-8 release in
response to cytokines and phorbol esters is differ-
ent between BEAS-2B and human primary airway
epithelial cells or airway cell lines.
The current study has found that pyocyanin
can further increase the production of IL-8 in
response to cytokine and phorbol ester stimula-
tion, in agreement with Denning’s study.4 This
synergism suggests that pyocyanin may increase
IL-8 release by preventing its degradation since
neither pyocyanin alone had any effect on IL-8
mRNA, nor pyocyanin influenced the levels
of cytokine- or phorbol ester-induced IL-8 mRNA.
However, the current study has not investigated
the post-transcriptional mechanism, which may
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Figure 5 Effects of dexamethasone (DEX), budesonide (BUD) and fluticasone (FLU) on PDBu-stimulated IL-8 release in
the presence of pyocyanin (Pyo) in BEAS-2B cells: (A) dexamethasone (10–1000 nM)+pyocyanin (5 mg/ml)+PDBu (0.3 mM);
(B) budesonide (1–100 nM)+pyocyanin (5 mg/ml)+PDBu (0.3 mM); (C) fluticasone (1–100 nM)+pyocyanin (5 mg/ml)+PDBu
(0.3 mM). Various glucocorticoids were added 30min before adding pyocyanin and PDBu. Supernatants were harvested
for measuring IL-8 by ELISA. Values were normalised to the maximal responses as 1.0, i.e. Pyo+PDBu and represent the
mean7SEM of 3–4 independent experiments in triplicate. *Po0:05; **Po0:01; ***Po0:001.
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Figure 4 Effects of dexamethasone (DEX), budesonide (BUD) and fluticasone (FLU) on IL-1b-stimulated IL-8 release in
the presence of pyocyanin (Pyo) in BEAS-2B cells: (A) dexamethasone (10–1000 nM)+pyocyanin (5 mg/ml)+IL-1b (1 ng/
ml); (B) budesonide (1–100 nM)+pyocyanin (5 mg/ml)+IL-1b (1 ng/ml); (C) fluticasone (1–100 nM)+pyocyanin (5 mg/
ml)+IL-1b (1 ng/ml). Various glucocorticoids were added 30min before adding pyocyanin and IL-1b. Supernatants were
harvested for measuring IL-8 by ELISA. Values were normalised to the maximal responses as 1.0, i.e. Pyo+IL-1b and
represent the mean7SEM of 3–4 independent experiments in triplicate. *Po0:05; **Po0:01; ***Po0:001.
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Figure 6 Effect of PKC inhibitor (Go6976; a selective
inhibitor of classic PKC isoforms) on pyocyanin-depen-
dent upregulation of IL-1b- or PDBu-induced IL-8 release
in BEAS-2B cells. (A) Go6976 (1–10 mM)+pyocyanin (Pyo;
5 mg/ml)+IL-1b (1 ng/ml); (B) Go6976+pyocyanin (5 mg/
ml)+PDBu (0.3 mM). Go6976 was added 30min before
adding pyocyanin and PDBu. Supernatants were har-
vested for measuring IL-8 by ELISA. Values were normal-
ised to the maximal responses as 1.0, i.e. Pyo+IL-1b or
Pyo+PDBu and represent the mean7SEM of 3–4 indepen-
dent experiments in triplicate. *Po0:05; **Po0:001.
N.Y. Pan et al.1620account for the effects observed with pyocyanin in
BEAS-2B cells.
There have been no reports on the effects of
glucocorticoids on IL-8 release stimulated by
pyocyanin in combination with IL-1b or PDBu.
Numerous studies have demonstrated that dexa-
methasone causes significant inhibition of cytokine-
or phorbol ester-mediated NF-kB activation and
IL-8 release.13,23–25 In this study, we were not able
to test the effect of glucocorticoids on pyocyanin-
stimulated IL-8 release alone. It is unclear whether
inhibiting pyocyanin-mediated mechanism plays a
role in glucocorticoid suppression on IL-8 releasestimulated by pyocyanin in combination with IL-1b
or PDBu. However, Denning and co-workers have
demonstrated that pyocyanin increased the expres-
sion of the IL-8 gene through activation of NF-kB, it
is likely that glucocorticoid inhibition may be
accomplished by inhibiting NF-kB.4 The in vitro
efficacy of budesonide is similar to that of
fluticasone, both being approximately 10 times
more potent than that of dexamethasone, in
agreement with the literature.26
Our finding that the PKC inhibitor Go6976
reduces IL-8 release stimulated by the combination
of pyocyanin and IL-1b or PDBu supports a role of
PKC in pyocyanin-dependent potentiation of IL-1b-
or PDBu-stimulated IL-8 release in BEAS-2B cells.
This is in contrast to the observation that PKC signal
pathway is not involved in pyocyanin-dependent
IL-8 release in A549 cells, as reported by Denning
and co-workers.4
Bronchiectasis is an inflammatory disease of
the bronchi with predominantly neutrophilic cel-
lular influx, triggered by an increase in IL-8
production by airway epithelium and inflam-
matory cells. The infiltrating inflammatory cells,
including neutrophils and macrophages, are an
abundant source of pro-inflammatory cytokines
such as TNF-a and IL-1b.27 The finding that
pyocyanin produced by P. aeruginosa may potenti-
ate or augment the stimulatory action of
pro-inflammatory cytokines on IL-8 release by
bronchial epithelial cells has important implica-
tions in the pathogenesis of bronchiectasis, which
further underscores the role of pyocyanin as a
major virulence factor responsible for the devel-
opment of the disease. Cytokines such as TNF-a and
IL-6 have been found to play a pro-inflammatory
role in maintaining the inflammation process pre-
sent in the bronchiectatic patients infected with
P. aeruginosa. Sputum in bronchiectasis has been
found to stimulate IL-6 production from bronchial
epithelial cells, which was not inhibited by dex-
amethasone, but TNF-a-stimulated IL-6 release was
inhibited.28
Bronchiectasis is a very common and largely
idiopathic disease among the Chinese.29 Similar to
cystic fibrosis, there are prominent chronic inflam-
matory and infective elements in the pathogenesis
of bronchiectasis. P. aeruginosa is the major
pathogen among these patients and is associated
with poor function, copious sputum production and
increased morbidity.2 P. aeruginosa produces a
number of phenazine pigments, and of these,
pyocyanin is generated in the largest quantities
locally in the lung.3 Phenzines are responsible for
the blue-green colour of the sputum that is
characteristic of infected patients.30
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Steroids Inhibit pyocyanin-potentiated IL-8 release 1621In conclusion, our data demonstrate that the
P. aeruginosa pigment, pyocyanin, upregulates
IL-1b- or PDBu-stimulated IL-8 release at clinically
relevant concentrations. Superinduction of IL-8
primed by pyocyanin among bronchiectatic pa-
tients with P. aeruginosa infection, could lead to
increase leukocyte trafficking into the lung. This in
turn would increase neutrophilic proteolytic en-
zymes, such as elastase and matrix metallopro-
tease-9 (MMP-9), which could digest the collagen
and structural elements of the airway leading to its
destruction and bronchiectatic dilatation.31,32 This
priming action of pyocyanin appears to be blocked
by glucocorticoids, thus providing in vitro data in
support of the clinical efficacy of inhaled gluco-
corticoids as anti-inflammatory drugs.33 However,
the data from others on cultured airway cells
demonstrate clearly the inhibitory effects of
several types of antioxidants including the thiol
antioxidant N-acetylcysteine (NAC) on pyocyanin-
dependent increases in IL-8.4,21 The results suggest
that antioxidants and glucocorticoids alone or in
combination as therapeutical approaches may be
more effective in reducing airway inflammation.
From the clinical point of view, the results of this
study indicate that bronchial epithelial cells by
producing IL-8 in response to pyocyanin and
proinflammatory cytokine IL-1b may contribute to
the maintenance of the self-perpetuating chronic
inflammatory cycle during P. aeruginosa infection in
bronchiectatic patients, in which glucocorticoids
are effective in the reduction of pro-inflammatory
cytokines.Acknowledgements
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